Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
July 14 2020 - 8:30AM
Celsion Corporation (NASDAQ: CLSN) will host a conference call and
webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss
its current observations about the results of the OPTIMA Study and
the Company’s next steps.
To access the conference call, interested
parties may dial 1-800-367-2403 (Toll-Free/North America) or
1-334-777-6978 (International/Toll) 10 minutes before the call is
scheduled to begin using the Conference ID 1879551. The conference
call will be webcast via the Investors page on the Company’s
website at https://investor.celsion.com/. The call will be archived
for replay through July 29, 2020. The replay can be accessed at
1-719-457-0820 or 1-888-203-1112 using Conference ID 1879551.
Approximately two hours following the live event, an audio replay
of the conference call will also be available on the Company’s
website for 90 days.
About Celsion Corporation
Celsion is a fully integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in development for other cancer indications. The
Company’s product pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian cancer.
Celsion has two platform technologies for the development of novel
nucleic acid-based immunotherapies and other anti-cancer DNA or RNA
therapies. For more information on Celsion, visit:
http://www.celsion.com. (CLSN-FIN).
Celsion wishes to inform readers that
forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data; the
significant expense, time, and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future
development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in Celsion's periodic reports and
prospectuses filed with the Securities and Exchange Commission.
Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Celsion Investor ContactJeffrey
W. ChurchExecutive Vice President &
CFO609-482-2455jchurch@celsion.com
LHA Investor RelationsKim Sutton
Golodetz212-838-3777kgolodetz@lhai.com
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024